University of California, LA

Los Angeles, California 99095

4 studies enrolling now · 26 studies all time

What they study most

Acute Lymphoblastic Leukemia, Advanced CCNE1-amplified Solid Tumors, Advanced HER2+Breast Cancer, Advanced HR+/HER2- Breast Cancer, Advanced Malignancies, Atherosclerotic Cardiovascular Disease, Barrett Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Chronic Lymphocytic Leukemia, Colorectal Cancer, Diffuse Large B-cell Lymphoma

Studies at this site

• Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers — Recruiting now
• Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors — Recruiting now
• An Extension Study for Patients Previously Enrolled in Studies With Pelabresib — Recruiting now
• A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study — Recruiting now
• Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss — Stopped early
• Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator — Completed
• A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors — Running, not enrolling
• Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation — Running, not enrolling
• An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) — Running, not enrolling
• Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL — Running, not enrolling
• Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 — Completed
• Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma — Running, not enrolling
• Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers — Completed
• Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. — Running, not enrolling
• A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors — Stopped early
• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) — Stopped early
• KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors — Stopped early
• Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis — Stopped early
• Patient Portal Flu Vaccine Reminders_RCT 4 — Stopped early
• Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus — Status unconfirmed
• Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- UCLA Portal R/R Influenza RCT 3 — Completed
• Patient Portal Reminder/Recall for Influenza Vaccination in a Health System- RCT 2 — Completed
• Pediatric Second Influenza Dose Portal Reminder Recall — Completed
• HPV IIS Reminder/Recall- New York State — Completed